anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To prospectively assess clinical and cost effectiveness of emergency ureteroscopic laser fragmentation of urinary stones causing symptoms or obstruction.
PATIENTS AND METHODS: 100 consecutive patients with an average (median) age 55.6 (57.5) years and average (median) stone size of 8.2 mm (± 7 mm) between October 2018 and December 2021 who underwent emergency ureteroscopy and laser fragmentation formed the study cohort as part of a clinical service quality improvement. Primary outcome was single procedure stone-free rate and cost-effectiveness. The secondary outcomes were complications, re-admission and re-intervention. A decision analysis model was constructed to compare the cost-effectiveness of emergency ureteroscopy with laser fragmentation (EUL) and emergency temporary stenting followed by delayed ureteroscopy with laser fragmentation (DUL) using our results and success rates for modelling.
RESULTS: Single procedure stone-free rates (SFR) for EUL and DUL were 85%. The re-intervention rate, re-admission and complication rates of the study cohort (EUL) were 9%, 18%, and 4%, respectively, compared to 15%, 20%, and 5%, respectively for the control cohort (DUL). The decision analysis modelling demonstrated that the EUL treatment option was more cost-efficient, averting £2868 (€3260) per patient for the UK health sector. Total cost of delayed intervention was £7783 (€8847) for DUL in contrast to £4915 (€5580) for EUL.
CONCLUSIONS: Implementation of quality improvement project based on a reduction in CT detection-to-laser fragmentation time interval in acute ureteric obstruction or symptoms caused by stones had similar clinical effectiveness compared to delayed ureteroscopic management, but more cost-effective.
PURPOSE: An adhesive polymer compound is provided to derive carrying growth factors for osteanagenesis and sustained-release emission. CONSTITUTION: An adhesive polymer is indicated in chemical formula 1. In chemical formula 1, n is an integer from 10-200, and m is an integer from 10-100. The adhesive nanoparticle is formed by self-assembling the adhesive polymer compound. The adhesive nanoparticle has a catechol group on surface thereof, poly(L-aspartate) on the shell, and poly(L-phenylalanine) on the core. The adhesive nanoparticle includes a drug, a growth factor, and a combination thereof on the core or the shell.
PURPOSE: A composition containing one or more among tea catechin and a cinnamomum extract for suppressing DKK1(Dickkopf-1) is provided to suppress DKK1, and to prevent or treat DDK1 expression-related diseases such as grey hair, alopecia, bone disease, obesity, and Alzheimer's disease. CONSTITUTION: A composition for suppressing DKK1 contains one or more among tea catechin and a Cinnamomum extract as active ingredients. The composition is used for treating and preventing obesity, Alzheimer's disease, or bone disease. The composition is also used for preventing and treating grey hair and alopecia. A pharmaceutical composition and a cosmetic composition contain the composition for suppressing DKK1. [Reference numerals] (AA) Suppress the expression of DKK1
Dental implants are considered a predictable rehabilitation option in the event of tooth extraction or missing tooth. In some cases, the inevitable resorption of the alveolar ridge after tooth extraction can make the insertion of dental implants difficult or even impossible without the use of more advanced bone regeneration procedures. Narrow diameter implants represent an alternative treatment option in areas with limited ridge width. Narrow alveolar ridges and limited interdental or inter-implant spaces continue to pose a challenge to the clinician. In the case of a narrow ridge, two options are available: the first option is to insert a standard diameter implant following bone augmentation procedures; the second option is to use an implant with a narrow diameter. Regarding the mesio-distal gap, an adequate distance between teeth and implants is necessary to reduce subsequent bone resorption and recession of the papillae. Difficult clinical situations with limited mesio-distal space or reduced ridge width can be overcome by using narrow diameter implants. Correct three-dimensional implant positioning is the key factor to obtain, in addition to good integration, favorable prosthetic results and a good long-term aesthetic result. To optimize the insertion of the implants, reducing the intrinsic imprecision of the conventional free-hand technique, computer-guided static surgery protocols can be used to plan the angulation, position and depth of the implant with a digital software. Narrow diameter implants therefore have their own indication for the replacement of lateral incisors of the maxilla and for the incisors of the mandible.
A traditional Chinese medicine transdermal patch for promoting blood circulation and clearing meridians to treat hyperplasia of the breast, comprising an adhesive layer, an energy layer, a magnetized layer, a medicinal film layer, and a backing layer. The backing layer is on the upper surface of the energy layer, and an air-impermeable film is on the lower surface of same. Below the air-impermeable film are, sequentially, a permanent magnet and the medicinal film layer. The outer side of the adhesive layer is the backing layer. The medicinal film layer is made from a composite of traditional Chinese medicine components and macromolecule material. The macromolecule material consists of a combination of PLA and PHB. The traditional Chinese medicine components are encapsulated within the macromolecule material. Heat produced by contact between a heat-emitting substance of the energy layer and oxygen acts on the medicinal layer, and is able to promote rapid release of traditional Chinese medicine active ingredients. The present patch is able to alleviate and dissipate pain and swelling caused by hyperplasia of the breast, while also being effective for treating cervical spondylosis, lower back and leg pain, chronic strain, spinal pain, rheumatic arthritis, osteoarthritis, and other chronic conditions.
BACKGROUND: Acute kidney injury (AKI) is a serious complication of cirrhosis. This study analyzed the prognostic effect of AKI in patients with cirrhosis and its risk factors, particularly in relation to amino acid imbalance.
METHODS: This retrospective study reviewed 808 inpatients with cirrhosis at two institutes in Gifu, Japan. AKI was diagnosed according to the recommendations of the International Club of Ascites. Amino acid imbalance was assessed by measuring serum branched-chain amino acid (BCAA) levels, tyrosine levels, and the BCAA-to-tyrosine ratio (BTR). Factors associated with mortality and AKI development were assessed using the Cox proportional hazards regression model with AKI as a time-dependent covariate and the Fine-Gray competing risk regression model, respectively.
RESULTS: Of the 567 eligible patients without AKI at baseline, 27% developed AKI and 25% died during a median follow-up period of 4.7 years. Using a time-dependent covariate, AKI development (hazard ratio [HR], 6.25; 95% confidence interval [CI], 3.98-9.80; p < 0.001) was associated with mortality in patients with cirrhosis independent of potential covariates. In addition, alcohol-associated/-related liver disease, metabolic dysfunction-associated steatohepatitis, Child-Pugh score, and BTR (subdistribution HR 0.78; 95% CI 0.63-0.96; p = 0.022) were independently associated with AKI development in patients with cirrhosis. Similar results were obtained in the multivariate model that included BCAA and tyrosine levels instead of BTR.
CONCLUSIONS: AKI is common and associated with mortality in Japanese patients with cirrhosis. An amino acid imbalance is strongly associated with the development of AKI in patients with cirrhosis.
Healthy men engaged in physical activity. Daily supplementation with the indicated protein preparation for a period of 8 weeks. MIX group receiving 30g of a preparation containing 80% rice and pea protein isolate.
Given that the intervention will be at the community level, a cluster randomized controlled trial is considered most appropriate for testing the hypothesis of this study. The intact groups/clusters of individuals (boaters) rather than individuals themselves, will be randomized to either intervention or control arm. The landing sites herein referred to as clusters, will be the randomization unit. This is because it is difficult to randomize individuals to behavioral intervention since they mix within the cluster. This study will be conducted using an etic epistemological approach guided by a realist ontology in order to objectively measure the effect of the intervention without the influence of the researchers.

To reduce covariate imbalance and increase comparability at baseline, clusters will be randomized to either intervention or control arm using stratified permuted block randomization, with landing sites (clusters) as the randomization unit. The clusters will be stratified by estimated population size and baseline prevalence of lifejacket use as compared with the overall average prevalence. All individuals in the intervention cluster will receive the intervention. The main aim of the stratified randomization is to ensure that the clusters are as comparable as possible at baseline. The other factors that might be considered for stratification will be identified at baseline and, in the opinion of the investigator, might interfere with the objectives of the study. Because there are few clusters per arm (7), two strata will be formed. The stratification variable will be the baseline prevalence of lifejacket wear in the landing sites.

The risk of contamination (one of the major threats to this study) will be reduced by ensuring that at least one cluster which is not part of the study acts as a buffer. From each stratum, one cluster will be randomly allocated to the intervention arm and the other to the control arm using stratified permuted block randomization with a 1:1 allocation ratio. The allocation will be generated using the 'sealed envelope TM' web-based application by an independent statistician who has no interest in the study. The block sizes will be masked/blinded to increase the randomness.
FIELD: veterinary science. SUBSTANCE: invention relates to method of treatment of visceral mycosis in rabbits caused by pathogenic fungus of genus Aspergillus fumigatus. Drug has 100 mg mebendazole in 1 ml water. Preparation is administrated to rabbits in volume 2-3 ml subcutaneously in scapula region, once per 24 h, for 2-3 days in a time, on 2-3-d day from sickness moment. EFFECT: enhanced effectiveness of treatment. 2 cl, 4 tbl
OBJECTIVES: I. Determine the toxicity profile, including dose limiting toxicity, and maximum tolerated dose (MTD) of combretastatin A4 phosphate in patients with advanced solid malignant tumors. II. Determine the pharmacokinetics of combretastatin A4 phosphate. III. Assess the effects of combretastatin A4 phosphate on tumor blood flow using PET and MRI scanning techniques, and establish the dose at which these effects occur. IV. Recommend a dose of combretastatin A4 phosphate for phase II evaluation based on tumor blood flow effect and the MTD. V. Evaluate possible antitumor effects of this regimen in these patients.

OUTLINE: This is an open label, dose escalation, multicenter study. Patients receive IV combretastatin A4 phosphate over 10 minutes once a week for 3 weeks. Patients not experiencing unacceptable toxic effects begin individual dose escalation, receiving a maximum of 3 dose levels with 2 weeks of rest between each dose level. Dose escalation stops when 2 patients have experienced dose limiting toxicity (DLT) at a particular dose level. Once DLT is established, at least 6 patients are treated at a lower dose to determine the maximum tolerated dose. Patients may receive up to 6 courses of 3 infusions each. Patients are followed for 4 weeks.

PROJECTED ACCRUAL: Approximately 30-35 patients will be accrued for this study.
Chemotherapy will be given depends on the cancer type and treatment regimen before enrollment. Chemotherapy was administrated on day1 , followed by Anti-PD-1 antibody 200mg on day2 IV Q3 weeks until progression.
Stem cell exosomes (Exo) play an important role in the transformation of macrophages, but the rapid clearance of Exo in vivo limits their therapeutic effects for chronic inflammation wounds healing. Here, stem cell Exo was isolated and introduced to a composite hydrogel including carboxymethyl chitosan (CMCS) and oxidized hyaluronic acid (OHA) through chemical cross-linking, which formed an Exo-loaded (CMCS/OHA/Exo) hydrogel. The CMCS/OHA/Exo hydrogel exhibited a function of Exo sustained release and an Exo protection within 6 days. This CMCS/OHA/Exo hydrogel was much better than CMCS/OHA hydrogel or Exo solution in macrophage cell phagocytosis, proliferation and migration in vitro, especially, played an obviously positive role in the transformation of macrophages compared with the reference groups. For the treatment of the chronic inflammation wounds in vivo, the CMCS/OHA/Exo hydrogel had the best results at wound heal rate and inhibiting the secretion of inflammatory factors, and it was far superior to reference groups in wound re-epithelization and collagen production. CMCS/OHA/Exo hydrogels can promote Exo release based on hydrogel degradation to regulate macrophages transformation and accelerate chronic wound healing. The study offers a method for preparing Exo-loaded hydrogels that effectively promote the transformation of macrophages and accelerate chronic inflammatory wound healing.
A combination of STARS developed by Mckeon et al. is planned for the STARS group. The training will be given for 6 weeks, 3 times a week for 5 minutes. STARS includes; joint mobilization, plantar massage and triceps surae stretching.
The world is currently facing serious danger due to COVID-19, even Korea, where is stated a good quarantine system, is confronting a serious risk of spread despite of a single group infection occurs. Taking this situation into consideration, it is intended to build a system that can check the spread path in real time. The business s print the bar code and attached it to the table after registering the information. Customers scan the attached bar code to the table through the downloaded app to register for entry when they visit the business s. If customers register their leave in the app, the date and time of leave will be recorded. When an infected person occurs, the customer's mobile phone number and visiting period will be searched and immediately extracted business s and customers with a potential for infection. Therefore, quarantine can be carried out.
Following pre-test period qualifying participants will wash their hands with 4% CHG product 3 times a day over the 5 day study period. Bacterial counts will be taken at 6 and 12 hours after the final wash on day 5 and reductions calculated from the starting count to final count.
The invention discloses a traditional Chinese medicine compound eye drop for preventing cataract and a preparation method of the traditional Chinese medicine compound eye drop. The preparation raw materials of the traditional Chinese medicine compound eye drop comprise the following ingredients in parts by weight: 45-60 parts of semen cassiae, 25-40 parts of flos buddlejae, 30-55 parts of herba erigerontis, 20-50 part of nux prinsepiae and 1 part of borneol. The traditional Chinese medicine compound eye drop is prepared by traditional Chinese medicines such as semen cassiae, flos buddlejae, borneol, herba erigerontis, nux prinsepiae and the like, and has the efficacy of removing slight corneal opacity and improving eyesight, and is used for improving and treating blurred vision and senile cataract. The compound eye drop has certain innovativeness in prescription selection and a certain social and economic value. Medicines for treating cataract currently are mainly prifenoxine (pirenoxine sodium) eye drop, and the preparation pharmacopoeia record for preventing cataract in a traditional Chinese medicine field is not available. The traditional Chinese medicine compound eye drop has the advantage of the traditional Chinese medicine prescription, and plays the characteristic of subtle droplet administration. The eye drop prepared by the method changes the history of no special efficacy medicines to treat senile cataract.
The first 5 steps of the Flemish Milk Ladder (each containing a, b and c part) will be gradually introduced at home, each step for 21 days (2-3X a week during 3 consecutive weeks after which 3 days "rest"). We consider the 6th step the equivalent of tolerance induction so step 6 will be allowed once the OFC with uncooked milk is passed.
<P>PROBLEM TO BE SOLVED: To provide a synthetic process facilely usable for the mass-preparation of tri- and tetra-substituted pyrimidine derivatives; and to provide a process by using minimum steps, and utilizing easily available starting material and a simple reaction medium.  <P>SOLUTION: The facile process for preparation of the tri- and tetra-substituted pyrimidines is provided. The process is useful for preparing inhibitors of protein kinases (especially Aurora kinase). These inhibitors are useful for treating or lessening the severity of Aurora-mediated diseases or conditions. The invention provides the method for treating cancer in a patient, and involves a process for administering a compound of formula V or a composition thereof to the patient.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Maladaptive cardiac hypertrophy contributes to the development of heart failure (HF). The oxidoreductase Selenoprotein T (SELENOT) emerged as a key regulator during rat cardiogenesis and acute cardiac protection. However, its action in chronic settings of cardiac dysfunction is not understood. Here, we investigated the role of SELENOT in the pathophysiology of HF: (i) by designing a small peptide (PSELT), recapitulating SELENOT activity via the redox site, and assessed its beneficial action in a preclinical model of HF [aged spontaneously hypertensive heart failure (SHHF) rats] and against isoproterenol (ISO)-induced hypertrophy in rat ventricular H9c2 and adult human AC16 cardiomyocytes; (ii) by evaluating the SELENOT intra-cardiomyocyte production and secretion under hypertrophied stimulation. Results showed that PSELT attenuated systemic inflammation, lipopolysaccharide (LPS)-induced macrophage M1 polarization, myocardial injury, and the severe ultrastructural alterations, while counteracting key mediators of cardiac fibrosis, aging, and DNA damage and restoring desmin downregulation and SELENOT upregulation in the failing hearts. In the hemodynamic assessment, PSELT improved the contractile impairment at baseline and following ischemia/reperfusion injury, and reduced infarct size in normal and failing hearts. At cellular level, PSELT counteracted ISO-mediated hypertrophy and ultrastructural alterations through its redox motif, while mitigating ISO-triggered SELENOT intracellular production and secretion, a phenomenon that presumably reflects the extent of cell damage. Altogether, these results indicate that SELENOT could represent a novel sensor of hypertrophied cardiomyocytes and a potential PSELT-based new therapeutic approach in myocardial hypertrophy and HF.
Well-differentiated endometrioid carcinoma (EC) is a low-grade cancer with relatively indolent behavior. However, even with well-differentiated histology, it sometimes tends to invade extensively and shows metastatic potential, suggesting that this is a group of cancers with heterogeneous behavior. In contrast, due to its tendency for younger onset, the treatment strategy for EC frequently considers fertility preservation, highlighting the need for a more accurate evaluation of myometrial invasion through biopsy and imaging diagnostics. We previously reported the involvement of the CXCR4-CXCL12 and CXCL14 axes in EC invasion. Accordingly, we investigated whether CXCR4 expression could reflect invasive potential and explored its interaction with cancer-associated fibroblasts that produce chemokines in the tumor microenvironment. Immunohistochemical expression of CXCR4 was assessed in 71 cases of EC (14 of EC confined to the endometrium and 57 of myoinvasive EC), 6 cases of endometrial intraepithelial neoplasia, and 42 cases of noncarcinomatous conditions. CXCR4 expression was significantly higher in myoinvasive EC than in noncancerous conditions, endometrial intraepithelial neoplasia, and endometrium-confined EC. By univariate and multivariate analysis, CXCR4 expression significantly reflected myometrial invasion. CXCR4 expression in the biopsied and resected specimens correlated weakly positively. Invasion and wound-healing assays were performed culturing an EC cell line in a cancer-associated fibroblast-conditioned medium. The invasion and wound-healing potentials were dependent on CXCR4 and cancer-associated fibroblast. Our study demonstrated that CXCR4 expression is an independent factor in myometrial invasion and can support diagnostic evaluation before treatment in the biopsy sample.
In this multicenter prospective phase 1/2A open label trial, the feasibility, tolerability and safety of intravenous immunoglobulin (IVIG) therapy following hepatic portoenterostomy (HPE) will be assessed in 29 infants with biliary atresia (BA), efficacy will be estimated and exploratory mechanistic research studies will be performed. After written consent is obtained from the parent or guardian, the subject will be enrolled and will receive three intravenous doses of IVIG at designated intervals over the first 60 days following HPE and will be followed for 360 days after enrollment. Blood will also be obtained during this study to assess potential mechanisms by which the IVIG may alter or reduce bile duct inflammation and injury and improve bile flow. All infants in this trial will also be treated with standardized doses of other routine standard-of-care treatments for BA during this trial (ursodeoxycholic acid, trimethoprim-sulfamethoxasole, and fat-soluble vitamin supplements). This routine clinical care will not be modified by participation in this study. Subjects in this study will not receive corticosteroid therapy for treatment of biliary atresia, as this is of unproven benefit at the present time.
PROBLEM TO BE SOLVED: To obtain a cosmetic giving excellent feeling such as dampishness and moistness, high humectant effect and softening effect to the skin by including a fruit water separated in the process for the concentration of fruit juice. SOLUTION: A cosmetic such as beauty wash, milky lotion, various creams, foundation, face lotion, rouge, beauty liquid and pack is compounded with a fruit water separated in a fruit juice concentrating process. The content of glucose and/or fructose in the fruit water is preferably <=0.5 wt.% and the compounding amount of the fruit water is preferably >=1 wt.% based on the produced cosmetic. Any fruit usable as a raw material for concentrated fruit juice can be used as the fruit and the examples of the fruit are apple, tangerine, orange and peach. The fruit water is e.g. water separated in a reverse osmosis membrane treatment of fruit juice comprising the passing of fruit juice through a tubular semipermeable membrane and the application of pressure to exclude water through the wall of the tubular membrane.